Abstract: Exemplary embodiments prevent tampering of a software release date associated with a software application by incorporating the software release date into a key exchange with a security domain. If the software release date is tampered with, then the key exchange results in the wrong key exchange key. Without the correct key exchange key, the software application will fail its check of the license, and the software application will no longer continue to run.

Abstract: Exemplary embodiments prevent tampering of a software release date associated with a software application by incorporating the software release date into a key exchange with a security domain. If the software release date is tampered with, then the key exchange results in the wrong key exchange key. Without the correct key exchange key, the software application will fail its check of the license, and the software application will no longer continue to run.

Abstract: Exemplary embodiments prevent tampering of a software date associated with a software application by incorporating the software date into a key exchange with a security domain. If the software date is tampered with, then the key exchange results in the wrong key exchange key. Without the correct key exchange key, the software application will fail its check of the license, and the software application will no longer continue to run.

Abstract: The invention provides compounds of formula I or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for inducing apoptosis or treating cancer using compounds of formula I.

Abstract: The invention provides compounds of formula I or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for inducing apoptosis or treating cancer using compounds of formula I.

Abstract: A method for anti-piracy protection of a software application by obfuscation of the execution of portions of the applications code is described. The method includes providing a language specification and library to implement the functions of the language, providing a compiler to translate the language into byte codes, and providing an interpreter to execute the byte codes using the library. The method further includes providing the language specifications, library, compiler, interpreter, and instructions to a software publisher, where the software publisher embeds the library and interpreter in the application to be protected, and selects and prepares application code segments for processing into byte codes by the compiler. The application is then executed using the embedded library and interpreter, where the execution of the application is obfuscated by the use of byte codes.

Abstract: An authorization system and associated method for selectively authorizing a host system to use one or more items of protected information associated with the host system. The authorization system includes a portable authorization device that is removably couplable to the host system. The portable authorization device is capable of receiving and storing multiple items of authorization information associated with a plurality of respective items of protected information from one or more information authorities. Preferably, the portable authorization device is capable of communicating with multiple types of information authorities. The portable authorization device selectively authorizes the host system to use the one or more respective items of protected information based upon the respective authorization information stored therein.

Abstract: The present invention provides compounds that are inducers or inhibitors of apoptosis or apoptosis preceded by cell-cycle arrest. In addition, the present invention provides pharmaceutical compositions and methods for treating mammals with leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells.

Abstract: The present invention provides compounds that are inducers or inhibitors of apoptosis or apoptosis preceded by cell-cycle arrest. In addition, the present invention provides pharmaceutical compositions and methods for treating mammals with leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells.

Abstract: Methods for treating or preventing breast cancer or leukemia in subjects in need of such treatment are provided which involve the administration of 6-[3-[1-adamantyl]-4-hydroxyphenyl]-2-naphthalene carboxylic acid (AHPN), a retinoid which induces G0/G1 arrest and apoptosis. These methods are useful for treatment of breast cancers which express or do not express estrogen receptors.

Abstract: The present invention provides compounds that are inducers or inhibitors of apoptosis of apoptosis preceded by cell-cycle arrest. In addition, the present invention provides pharmaceutical compositions and methods for treating mammals with leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells.